| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 8.240 | 9.863 | 9.429 | 6.804 | 30.484 | 16.075 | 32.781 | 58.648 | - | 35.593 |
| Total Income - EUR | 8.247 | 10.024 | 9.429 | 6.942 | 30.627 | 16.612 | 32.849 | 60.403 | - | 36.873 |
| Total Expenses - EUR | 7.094 | 9.152 | 15.532 | 7.611 | 10.702 | 13.344 | 11.530 | 12.580 | - | 29.804 |
| Gross Profit/Loss - EUR | 1.153 | 871 | -6.103 | -669 | 19.925 | 3.268 | 21.319 | 47.822 | - | 7.069 |
| Net Profit/Loss - EUR | 906 | 571 | -6.386 | -873 | 19.006 | 2.781 | 20.397 | 46.010 | - | 5.938 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 |
Check the financial reports for the company - Neopharma Marketing & Consulting S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 11.626 | 9.194 | 5.768 | - | 11.228 |
| Current Assets | 14.689 | 16.047 | 12.505 | 16.647 | 44.036 | 42.325 | 68.384 | 46.534 | - | 51.733 |
| Inventories | 6.533 | 6.466 | 0 | 0 | 148 | 0 | 0 | 0 | - | 0 |
| Receivables | 2.112 | 2.465 | 3.093 | 4.499 | 26.495 | 7.713 | 8.055 | 8.837 | - | 31.562 |
| Cash | 6.044 | 7.117 | 9.412 | 12.148 | 17.393 | 34.612 | 60.330 | 37.697 | - | 20.171 |
| Shareholders Funds | 11.601 | 6.739 | 240 | -638 | 18.381 | 20.814 | 40.750 | 51.712 | - | 67.193 |
| Social Capital | 2.835 | 2.806 | 2.758 | 2.708 | 2.655 | 2.605 | 2.547 | 2.555 | - | 2.533 |
| Debts | 3.088 | 9.308 | 12.265 | 17.284 | 25.655 | 33.136 | 36.829 | 590 | - | 6.029 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Neopharma Marketing & Consulting S.r.l.